TEM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tempus AI Inc (TEM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, improving financials, positive hedge fund activity, and recent product launches position it well for future growth. Despite mixed analyst ratings and some concerns about its data business, the current valuation and growth potential make it an attractive opportunity.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 69.669, and moving averages are converging, suggesting a potential breakout. The pre-market price of $55.49 is near the first resistance level (R1: 55.535), signaling potential upward movement.
Hedge funds are significantly increasing their positions in the stock (+884.13% last quarter).
Recent product launches like GenoPredicta™ and automated clinical update services highlight innovation and market relevance.
Strong revenue growth (+82.98% YoY) and improving gross margin (64.73%).
Positive sentiment from TD Securities and Guggenheim, who see growth potential in AI and genomics.
Mixed analyst ratings with Jefferies initiating an Underperform rating and concerns about the company's data business and unclear catalysts.
Net income remains negative (-$54.16M in Q4 2025), though it has improved YoY.
No recent congress trading data or AI trading signals to reinforce confidence.
In Q4 2025, Tempus AI reported revenue growth of 82.98% YoY to $367.21M. Net income improved by 316.21% YoY to -$54.16M, and EPS increased by 275% YoY to -$0.3. Gross margin improved to 64.73%, up 6.41% YoY, reflecting better operational efficiency.
Analyst ratings are mixed. TD Securities upgraded the stock to Buy with a $65 price target, citing undervaluation and growth potential in AI and genomics. Guggenheim and Baird also maintain Buy/Outperform ratings. However, Jefferies initiated coverage with an Underperform rating and a $35 price target, citing concerns about the company's data business and lack of clear catalysts.
